Product Details
| Product Name:
Phenoxodiol |
CAS No.:
81267-65-4 |
| Purity:
99.18% |
Supply Ability:
10g |
| Release date:
2025/12/05 |
Product Introduction
Bioactivity
| Name | Phenoxodiol |
| Description | Phenoxodiol (Idronoxil) activates the mitochondrial caspase system, inhibits X-linked inhibitor of apoptosis(XIAP), disrupts FLICE inhibitory protein(FLIP) expression, and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21WAF1 via a p53 independent manner. Phenoxodiol also inhibits DNA topoisomerase II. |
| In vitro | Phenoxodiol, at concentrations >or=1 microg/ml (4 microM), inhibited proliferation and reduced the viability of healthy donor-derived PBMC. In contrast, lower Phenoxodiol concentrations (0.05-0.5 microg/ml) augmented, upon 3-day incubation, peripheral blood mononuclear cells cytotoxicity. Experiments with purified CD56(+) lymphocytes revealed that Phenoxodiol enhanced the lytic function of natural killer cells by directly stimulating this lymphocytic subpopulation[3]. |
| In vivo | Balb/C mice administered low-dose Phenoxodiol exhibited significantly reduced tumour growth rates and prolonged survival (in 40% of the animals) in a colon cancer model[3]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50 mg/mL (208.12 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (8.32 mM), Sonication is recommended.
|
| Keywords | XIAP | topoisomerase II | Topoisomerase | prostate cancer | Phenoxodiol | p53 | ovarian cancer | Inhibitor | inhibit | DNA topoisomerase II | CP70 | Caspase | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | 1,4-Naphthoquinone | L-Methionine | Dimethyl phthalate | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Apoptosis Compound Library | Anti-Lung Cancer Compound Library | Cuproptosis Compound Library | Anti-Pancreatic Cancer Compound Library | ReFRAME Related Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Metabolism Compound Library | Anti-Aging Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
-
CAS:1445879-21-9
$40.00 / 1mg
-
CAS:5407-57-8
$46.00 / 100mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States